Sysmex : The 20th Technology Presentation(

The 20th R&D Meeting

March 3, 2023

Sysmex Corporation

Index

1. Opening Presentation
2. R&D Initiatives under the Mid-Term Management Plan

3 Creation of Testing Value in Key Domains in MTP

4 Initiatives for Diagnosis of the Central Nervous System Disease

Hisashi Ietsugu

Chairman and CEO

Kaoru Asano

Member of the Managing Board and

Senior Executive Officer

Senior Managing Director, CTO

Tatsuya Ohashi

Executive Vice President, Reagent Engineering Division

Tomokazu Yoshida

Member of the Managing Board

and Senior Executive Officer

Managing Director

Glossary

■The information contained in these materials is based on current judgements and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments in Japan and overseas may cause plans to change.

■These materials contain information about products, service and support (including those under development). This information

is not intended for advertising or promotional purposes.	2

1	Opening Presentation

Hisashi Ietsugu

Chairman and CEO

3

Sysmex's Corporate Philosophy and the Source of Value Creation

Long-Term

Management

Goals

(2025)

Mid-Term

Management Plan

(through March 2024)

Long-Term Vision

Unique & Advanced Healthcare Testing Company

Positioning Targets

• Creating innovative diagnostic value as a global top-five company in IVD
• A leading company in personalized diagnostics for optimizing medical treatment
• A solution provider contributing to the advancement of primary care diagnostics
• An attractive company providing value and instilling confidence
• One Sysmex carrying out high-speed management

Source of value creation

Technology platforms

Cell measurement

Protein measurement

Gene measurement

Provision of products, services and quality

Instruments					Quality
Specialized
reagents					control
IT / software

4

Changes in the Operating Environment and Initiatives over the Past 20 Years

Technology Healthcare

		2000s			2010s			2020s
 Introduction of molecularly	 Growing healthcare disparities	 COVID-19 Pandemic
	targeted therapeutic drugs	among countries and regions due	 Adoption of online medicine
 From treatment to prevention	to increasingly sophisticated testing	 Optimization of medical
	(lifestyle diseases)	 Further increases in medical	expenses
				expenses
 Sequencing of the human genome	 Rise of next-generation sequencers	 Realization of personalized
 Rise of gene detection technology	 Leap forward in high-speed	diagnostics
 Electronic medical charges and	communication technology	 Implementation of liquid biopsy
	other use of ITC in healthcare	 Advances in automation technology	 Implementation of remote and
							virtual technologies

Sysmex

• R&D expenses: Approx. ¥4.0 billion

(FY2001 Results)

• Opening of Central Research Laboratories
• Opening of Technopark

• Liquid biopsy initiatives
• Expansion of unique testing

(OSNATM, hepatic fibrosis markers, etc.)

• Reinforcement of IT products
• Strengthening of global development structure

• R&D expenses: Approx. ¥33.5 billion,

( FY2022 Forecast)

• Global rollout of the XRTM-Series
• Advances in unique tests

(testing for Alzheimer's disease, etc.)

5